6 results
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
To test the hypothesis that mirikizumab is superior to placebo in inducing clinical remission at Week 12 in patients with moderately to severely active ulcerative colitis (UC)
Study AMAP is a single-arm, outpatient, open-label, Phase 3, multicenter, long-term extension study evaluating the efficacy and safety of mirikizumab in patients with moderately to severely active UC who have participated in an originator…
To test the hypothesis that mirikizumab is superior to placebo in maintaining clinical remission at Week 40 (Week 52 of continuous therapy) among patients induced into clinical remission with mirikizumab
1) To evaluate the efficacy and safety of the standard clinical care at the AMC in this patient population by the clinical outcomes (recurrent) thrombotic events and bleeding complications respectively.2) To evaluate the change in quality of life in…
To measure DOAC levels just before surgery of all DOAC patients in the LUMC with elective surgery for which ceasing of DOAC treatment is required.